synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
LiveNation (which already operates music venues at the site) will revamp the Budweiser Stage Amphitheatre into an indoor/outdoor facility with a capacity of up to 20,000 people in the summer and nearly 9,000 in winter. Austrian company Therme Group will develop the west island. A new large facility will cover most of the island. The facility will include indoor and outdoor pools, a spa, waterslides, restaurants, and a botanical garden. Outside of the facility, it will build a 12 acres (4.9 ha) public park and beach. The projected admission price for indoor activities is about $40 per person for full-day admittance. A third company proposed to build a zip-line and adventure park but pulled out of the project. The company and the government could not come to terms on the lease. Private sector investments are expected to be about $500 million. Public sector investment was not disclosed. A review process for environmental, heritage, and public consultation will likely extend into 2023. Construction is scheduled to begin in 2024, with a 2030 completion. In February 2022, Toronto city council voted to adopt a process to create an approvals process for the Province's plan for the redevelopment of Ontario Place. This process generally follows the city's traditional development approvals process, notwithstanding Ontario Place is predominately constructed on Provincially-owned land. Based on this timeline, a rezoning application is expected in late 2022 and a site plan approval process began in 2023. The Cinesphere was closed for renovations.
== Effects of the Closure == Madera Community Hospital was the only hospital within a 30 mile radius, thus the closure caused 160,000 Madera residents to not have access to a local emergency room. Many people were faced with driving the 45 minutes to one of the neighboring towns or not receiving proper treatment. Unfortunately, this decision was already made for residents without access to a vehicle or public transportation. Other hospitals in the Central Valley were then stressed by the pressures of taking on all of the patients who would have previously been treated in Madera, which caused significant increases in emergency room wait times. Private ambulance companies from other counties pitched in to help take calls from Madera to transport residents to other hospitals such as Saint Agnes Medical Care (Fresno) and Community Regional Medical Center (Fresno). Not only were the patients redirected, 772 employees across the four locations were laid off when the hospital shuttered its doors.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed HBTU is a moderate skin sensitizer, showing a response at 0.9 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows HBTU is potentially explosive.
Sources: en.wikipedia.org
=== Protists === Hydroxyproline is also found in the walls of oomycetes, fungus-like protists related to diatoms. Phytophthora cactorum specifically produces a pathogenic protein containg 4-hydroxyproline.
In the 1961 season, he guest-starred in an episode of NBC's Western Bonanza titled "Broken Ballad". In the 1961–1962 season, he guest-starred on ABC's crime drama Target: The Corruptors! and that network's The Rifleman. In the 1962–1963 season, he guest-starred in NBC's modern Western series Empire starring Richard Egan. In 1964, Culp played Charlie Orwell, an alcoholic veterinarian, in an episode of The Virginian (NBC 1962–1971) titled "The Stallion". That same year, he appeared in yet another Western, Gunsmoke. In the series' episode "Hung High", he portrays an outlaw named Joe Costa, who attempts to frame Matt Dillon for lynching a prisoner who had killed the marshal's friend. In 1965, he was cast as Frank Melo in "The Tender Twigs" of James Franciscus's NBC education drama series, Mr. Novak. Culp then played perhaps his most memorable character, American secret agent Kelly Robinson, who operated undercover as a touring tennis professional, for three years on the hit NBC series I Spy (1965–1968), with co-star Bill Cosby. Culp wrote the scripts for seven episodes, one of which he also directed and an episode earned him an Emmy nomination for writing. For all three years of the series, he was also nominated for an acting Emmy (Outstanding Performance by an Actor in a Leading Role in a Dramatic Series category), but lost each time to Cosby.
== Further reading == Hồ NT, Hughes SG, Ta VT, Phan LT, Đỗ Q, Nguyễn TV, et al. (May 2024). "Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials". Nature Communications. 15 (1) 4081. Bibcode:2024NatCo..15.4081H. doi:10.1038/s41467-024-47905-1. PMC 11094049. PMID 38744844.
Most substances relevant to biology are chiral, such as carbohydrates (sugars, starch, and cellulose), all but one of the amino acids that are the building blocks of proteins, and the nucleic acids. Naturally occurring triglycerides are often chiral, but not always. In living organisms, one typically finds only one of the two enantiomers of a chiral compound. For that reason, organisms that consume a chiral compound usually can metabolize only one of its enantiomers. For the same reason, the potencies or effects of enantiomers of a pharmaceutical can differ sharply.
Sources: en.wikipedia.org
James Albert Hird (born 4 February 1973) is a former professional Australian rules football player and past senior coach of the Essendon Football Club in the Australian Football League (AFL). Hird played as a midfielder and half-forward, but he was often given free rein by then-Essendon coach Kevin Sheedy to play wherever he thought necessary. Hird was a highly decorated footballer, with accolades including the 1996 Brownlow Medal and membership of the Australian Football Hall of Fame. In 2008, he was listed by journalist Mike Sheahan as the 20th greatest player of all time in the AFL-commissioned book The Australian Game of Football. Hird was appointed as the coach of the Essendon Football Club in September 2010. In August 2013, he was suspended from coaching for 12 months when he was charged by the AFL with conduct prejudicing the game in relation to his role in the Essendon Football Club supplements controversy. He returned to the club following the 2014 season but resigned in August 2015.
===== Adverse effects ===== Common adverse effects elicited by these drugs include hot flushes, bone loss, headache, unpredictable mood changes, depression, vaginal dryness, or even atrophy for females and penile atrophy for males. These adverse effects can be counteracted and treated by add-back therapy, also known as hormone replacement therapy. People treated with GnRH agonists are suggested to undergo this therapy simultaneously by taking adequate progestin, vitamin D, and calcium supplement pills daily.
=== Differential diagnosis === The signs and symptoms of microscopic polyangiitis may resemble those of granulomatosis with polyangiitis (GPA) (another form of small-vessel vasculitis) but typically lacks the significant upper respiratory tract involvement (e.g., sinusitis) frequently seen in people affected by GPA.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.